Billionaire Club Fueled by Strong Financial Performance

The compensation of CEOs at major global pharmaceutical companies, including Eli Lilly and AbbVie, increased significantly last year. David Ricks, CEO of Eli Lilly, received $36.7 million, a 25% increase, driven by the blockbuster success of obesity treatment Zepbound (tirzepatide) and diabetes drug Mounjaro. Robert Michael, CEO of AbbVie, saw his compensation jump 75% to $32.5 million, with revenue growing by 8% thanks to the strong performance of immunology drugs Skyrizi (risankizumab) and Rinvoq (upadacitinib). These compensation increases are not merely expenses but reflect the successful market launch of new drugs and the resulting maximization of shareholder value.

Leadership Rewarded for Overcoming Patent Expiry and Regulatory Hurdles

Joaquin Duato, CEO of Johnson & Johnson, received $32.8 million for successfully defending against the loss of exclusivity (LOE) of Stelara (ustekinumab), a blockbuster drug for autoimmune diseases. Despite the patent cliff, his leadership in growing the alternative pipeline and managing risks effectively to maintain market share was rewarded. Emma Walmsley, CEO of GSK, who is about to retire, received $21 million for successfully negotiating a Most-Favored Nation (MFN) price agreement with the U.S. government, avoiding tariff risks. This demonstrates that the ability of management to overcome regulatory hurdles and ensure business stability in crisis situations is recognized as a core value of the company.

Pfizer's M&A Success Shines Despite Financial Underperformance

Despite a 2% decline in revenue due to decreased demand for COVID-19 vaccines, Albert Bourla, CEO of Pfizer, received $27.6 million, attracting industry attention. Although shareholders recommended against it, the board approved the increase, recognizing the company's aggressive pipeline expansion, including the acquisition of obesity treatment specialist Metsera for $10 billion and the acquisition of global rights to the bispecific antibody SSGJ-707 from China's 3SBio for $6 billion. This indicates that management's ability to secure future growth drivers through major deals and portfolio restructuring, even in the face of short-term financial difficulties, is a key indicator of performance. The company's efforts to implement a $5.7 billion cost reduction program by 2026 to ensure financial stability were also positively evaluated.

Competition in the Oral Obesity Treatment Market and Market Restructuring

The recent increase in CEO compensation is driven by the explosive growth of the obesity treatment market and the fierce competition among pharmaceutical companies to gain a foothold. Eli Lilly, with its recently approved oral GLP-1 receptor agonist Foundayo (orforglipron), is preparing to challenge Novo Nordisk's dominance in the obesity market with Wegovy. Pfizer is also accelerating clinical trials of oral obesity treatments, such as YP05002, acquired from YaoPharma, in an attempt to restructure the market. As a result, management compensation is increasingly determined in proportion to strategic decision-making and R&D performance aimed at securing the next-generation mega-blockbuster market.